CAR T-Cell Therapy in Multiple Myeloma

Authors

DOI:

https://doi.org/10.46765/2675-374X.2025v7n1e390

Keywords:

Car-T cell, Immunotherapy, Multiple myeloma

Abstract

The introduction of CAR (chimeric antigen receptor) T-cell therapy into clinical practice has revolutionized the treatment landscape of relapsed/refractory multiple myeloma (RRMM). At present, two B-cell maturation antigen (BCMA)-targeted CAR T-cell therapies, idecabtagene vicleucel and ciltacabtagene autoleucel, are used in clinical practice, but only ciltacabtagene autoleucel is approved in Brazil. In this review, we explore the advantages and challenges of integrating CAR T-cell therapy earlier in the RRMM treatment course.

References

1. Rajkumar SV, Kumar SK. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020; 10(9): 94. https://doi.org/10.1038/s41408-020-00359-2

2. Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibodies. Leukemia. 2019;33:2266–75. https://doi.org/10.1038/s41375-019-0435-7

3. Tai Y-T, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015; 7(11): 1187–99. https://doi.org/10.2217/imt.15.77

4. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5. https://doi.org/10.1126/science.aar6711

5. Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16. https://doi.org/10.1056/NEJMoa2024850

6. Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel vs standard regimens in relapsed multiple myeloma (KarMMa-3). N Engl J Med. 2023;388(11):1002–14. https://doi.org/10.1056/NEJMoa2213614

7. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel in relapsed or refractory multiple myeloma. Lancet. 2021;398(10297):P314–24. https://doi.org/10.1016/S0140-6736(21)00933-8

8. Martino M, Bilardi E, Pitea M, Porto G, Policastro G, Utano G, et al. BCMA-Targeted Immunotherapy in Early Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Practical Management. Eur J Haematol. [Preprint] 2026. https://doi.org/10.1111/ejh.70328

9. Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, et al. Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/ Refractory Multiple Myeloma. J Clin Oncol. 2025;43(25):2766–71. https://doi.org/10.1200/JCO-25-00760

10. San-Miguel J, Weisel K, Moreau P. Ciltacabtagene autoleucel vs standard care in relapsed multiple myeloma (CARTITUDE-4). N Engl J Med. 2023. https://doi.org/10.1056/NEJMoa2303379

11. Einsele H, San-Miguel J, Dhakal B, Touzeau C, Leleu X, van de Donk NWCJ, et al. Cilta-cel in lenalidomiderefractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an openlabel, multicentre, randomised, phase 3 trial. Lancet Oncol. 2026;27(2):P254–68. https://doi.org/10.1016/S1470-2045(25)00653-9

12. Mateos MV, Weisel K, van de Donk N. LocoMMotion: a study of real-life current standards of care in tripleclass exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis). Leukemia. 2024;38(12):2554–60. https://doi.org/10.1038/s41375-024-02404-6

13. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for CRS and neurologic toxicity. Biol Blood Marrow Transplant. 2019;25(4):625–38. https://doi.org/10.1016/j.bbmt.2018.12.758

14. Wronski M, Wesselingh R, Kazzi C, Seery N, Ko K, Li J, et al. Neurotoxicity associated with chimeric antigen receptor T-cell therapy. J Neuroimmunol. 2025;407:578717. https://doi.org/10.1016/j.jneuroim.2025.578717

15. Mohan M, Chakraborty R, Bal S, Nellore A, Baljevic M, S’Souza A, et al. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Br J Haematol. 2023;203(5):736–46. https://doi.org/10.1111/bjh.18909

16. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505. https://doi.org/10.1056/NEJMoa2203478

17. Alvaro ME, Martino EA, Caserta S, Skafi M, Bruzzese A, Amodio N, et al. Elranatamab in Relapsed/ Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives. Eur J Haematol. 2026;117(1):42-54. https://doi.org/10.1111/ejh.70167

Downloads

Published

11/20/2026

How to Cite

Maiolino, A., Kerbauy, M. N., Magalhães, R. J. P. de, Souza, F. V. P. de, Souto Filho, J. T. D., Crusoé , E. de Q., … Hungria, V. T. de M. (2026). CAR T-Cell Therapy in Multiple Myeloma. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 7(1). https://doi.org/10.46765/2675-374X.2025v7n1e390